Close

Aerpio Pharmaceuticals (ARPO) and Aadi Bioscience Enter into a Definitive Merger Agreement

Go back to Aerpio Pharmaceuticals (ARPO) and Aadi Bioscience Enter into a Definitive Merger Agreement

Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement

May 17, 2021 7:00 AM EDT

Transaction to create Nasdaq-listed company focused on advancing Aadi Biosciences late-stage pipeline for genetically-defined cancers with alterations in mTOR pathway genesConcurrent $155 million PIPE financing is backed by leading life science investors led by Acuta Capital Partners and KVP Capital and including Avoro Capital Advisors; Avoro Ventures; Venrock Healthcare Capital Partners; BVF Partners, L.P.; Vivo Capital; Alta Bioequities, L.P.; Rock Springs Capital; RTW Investments, LP; Acorn Bioventures; and Serrado Capital LLCCombined company cash at closing will fund operations into... More